Draft guidance published for an immunotherapy treatment that could prevent blood cancer from returning in adults who've ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication ...

A list of downloadable documents created during development.

Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...